Trial Profile
The Effect of Sodium Glucose Co-transporter 2 (SGLT2)-Inhibitors on Sleep Disordered Breathing in Heart Failure Patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- 31 Jul 2023 Planned End Date changed from 1 Dec 2022 to 1 Aug 2025.
- 31 Jul 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Aug 2025.
- 31 Jul 2023 Planned initiation date changed from 1 Apr 2022 to 1 Dec 2023.